| Sex |
|
|
|
|
|
| Female |
23 |
77 |
|
|
|
| Male |
7 |
23 |
|
|
|
| Age at disease onset (year) |
|
6.5±5.2 |
|
|
| Age at study visit (year) |
|
8.8±5.3 |
|
|
| Duration of the disease (year) |
|
2.3±3.4 |
|
|
| JIA subtype |
|
|
|
|
|
| Oligoarthritis |
17 |
57 |
|
|
|
| Rheumatoid factor negative polyarthritis |
7 |
23 |
|
|
|
| Rheumatoid factor positive polyarthritis |
1 |
3 |
|
|
|
| Systemic arthritis |
2 |
7 |
|
|
|
| Enthesitis-related arthritis |
2 |
7 |
|
|
|
| Psoriatic arthritis |
1 |
3 |
|
|
|
| Disease activity |
|
|
|
|
| Juvenile Arthritis Disease Activity Score-27 |
|
15 |
6-47 |
| Therapy at study visit* |
|
|
|
|
| Nonsteroidal anti-inflammatory drugs |
25 |
83 |
|
|
|
| Methotrexate |
9 |
30 |
|
|
|
| Sulfasalazine |
1 |
3 |
|
|
|
| Etanercept |
1 |
3 |
|
|
|
| Systemic corticosteroids |
5 |
17 |
|
|
|
| Intra-articular corticosteroids |
5 |
17 |
|
|
|
|
SD: Standard deviation; * These are the drugs that patients were receiving at the time of involvement in the study. Some patients used several drugs simultaneously. After collecting of blood samples for the determination of interleukin-17A, therapy was adjusted with other necessary medications for the treatment of juvenile idiopathic arthritis.
|
